Icahn scores a fortune on two big biotech plays

Carl Icahn may be the last person you'd want to see knocking on your biotech's front door, but investors who went along on his joyride at Biogen Idec and Genzyme have profited handsomely. Boston Globe columnist Steve Syre did the math and concluded that Icahn earned $614 million on his investment in Biogen and $237 million more on Genzyme. Altogether, that's a gain of $851 million. Says Syre: Executives don't like his rough tactics, but no one can argue about the results. Column

Suggested Articles

No biohazardous substances were in the room where the explosion happened, according to the Russian virology center.

Merck has a shot at becoming the first company to receive clearance to sell a vaccine against the virus in the U.S.

Acceleron has chalked up another phase 2 flop as its pipeline thins a little more.